drugset / Trial / NCT05594615

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

NCT05594615

Phase 1 Completed 24 enrolled Enanta Pharmaceuticals, Inc
NaSingle-groupOpen-labelTreatment

Summary

A Drug-Drug Interaction study to assess the effects of EDP-235 on the Pharmacokinetics and Safety of midazolam, caffeine and rosuvastatin.

Timeline

Start
2022-10-06
Primary completion
2022-11-04
Completion
2022-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule
Subject EDP-235 Unknown
Subject Midazolam Small molecule
Subject Rosuvastatin Small molecule

Indications